Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2023-04-30 Regulatory Filings
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Section 708A Cleansing Notice 2 pages 511.1KB
Regulatory Filings Classification · 95% confidence The document is a Section 708A Cleansing Notice issued by Prescient Therapeutics Limited under the Corporations Act 2001 (Cth). It confirms the issuance of shares due to the exercise of options by directors and compliance with disclosure requirements. The document is a regulatory announcement related to share issuance and compliance, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is 5730 characters, which is relatively short and focused on a specific regulatory compliance notice. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-30 English
Application for quotation of securities - PTX 6 pages 28.9KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and mentions key management personnel involved in the conversion. The document is regulatory in nature, announcing a capital change related to securities issuance and quotation. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement but a formal application for quotation, supporting this classification.
2023-04-30 English
March 2023 Quarterly Update and Appendix 4C 13 pages 1.6MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed quarterly activities report from Prescient Therapeutics, covering clinical trial progress, financial updates including cash balances and option exercises, business development, and ongoing research programs. It includes substantive financial data such as cash outflows, payments to related parties, and cash balances, as well as operational highlights and clinical trial updates. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with a comprehensive interim or quarterly report providing financial results and operational updates for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-04-27 English
Exercise and Expiry of Listed Options 3 pages 963.5KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the exercise and expiry of listed options, detailing the number of options exercised, the total consideration received, and the number of options expired unexercised. It also includes a description of the company's business and products, contact information, and a forward-looking statements disclaimer. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is focused on capital market activity related to option exercises, which is a financing event. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (9278 characters) is sufficient to be a full announcement rather than a brief notice or report publication announcement.
2023-04-03 English
Application for quotation of securities - PTX 6 pages 28.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. There is no financial performance data, management discussion, or audit information. The document fits the category of announcements regarding new share issues or capital changes.
2023-04-03 English
Change of Director's Interest Notices x2 7 pages 411.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the number of shares and options held before and after the change, dates of changes, and nature of transactions such as exercise of options. This type of document is a formal notification of personal share transactions by company directors. It is not a financial report, earnings release, or management discussion. It fits precisely the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is the actual notice, not just an announcement or certification. Therefore, the correct classification is DIRS.
2023-04-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.